Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 374

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 374
---
 and consequently over decisions related to the activities of Opella, thereby leading to the loss of control by Sanofi over Opella based on the criteria for assessment of control specified in IFRS 10 and the Basis of Conclusions thereto. BpiFrance is expected to participate as a minority shareholder with a c.2% stake in Opella, which does not change the analysis of control set forth above. With effect from the date of closing of the transaction, Sanofi will exercise significant influence over Opella. The share of profits or losses from the retained interest in Opella will then be reported within the line item Share of profit/(loss) from investments accounted for using the equity method in the Sanofi income statement. Completion of the transaction is considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7.), all assets of Opella and all liabilities directly related to those assets are classified from October 21, 2024 in the line items Assets held for sale and Liabilities related to assets held for sale , respectively, in the consolidated balance sheet (see Notes D.8. and D.36.). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information"). Consequently, Opella meets the definition of a discontinued operation under IFRS 5 (see Note B.7.), as a result of which the net income from this business is presented separately within the line item Net income from discontinued operations in the consolidated income statement. This presentation in a separate income statement line item applies to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business are also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented. For detailed information about the contribution of the Opella business to the consolidated financial statements refer to Note D.36., “Information related to Opella ”. D.1.1.3. Enjaymo divestment On November 29, 2024, Sanofi entered into a definitive agreement with Recordati for the sale of Sanofi's global rights to Enjaymo and the transfer of specific employees. Under this agreement, Sanofi received an upfront payment of $ 825million and will be eligible for milestone